Compare uniQure N.V. Ordinary Shares (QURE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs GeneDx Holdings Corp — how do they compare? uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is more actively traded (524,385 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| QURE | WGS | |
|---|---|---|
Market Cap | $1.48B | $1.94B |
Volume | 2,488,780 | 524,385 |
Sector | Health | Health |
52-Week High | $70.59 | $167.51 |
52-Week Low | $9.03 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $728.62M | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
